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Purification and scale-up of a recombinant heavy chain
fragment C of botulinum neurotoxin serotype E
in Pichia pastoris GS115

Abstract
A recombinant C-terminus heavy chain fragment from botulinum neurotoxin serotype E (BoNT/E) is
proposed as a vaccine against the serotype E neurotoxin. This fragment, rBoNTE(Hc), was produced
intracellular in Pichia pastoris GS115 by a three-step fermentation process, i.e., glycerol batch phase and a
glycerol fed-batch phase to achieve high cell densities, followed by a methanol fed-batch induction phase. The
rBoNTE(Hc) protein was purified from the soluble fraction of cell lysates using three ion-exchange
chromatography steps (SP Sepharose Fast Flow, Q Sepharose Fast Flow, Sp Sepharose High Performance) and
polished with a hydrophobic charge induction chromatography step (MEP HyperCel). Method development at
the bench scale was achieved using 7– 380 mL columns and the process was performed at the pilot scale using
0.5–3.1 L columns in preparation for technology transfer to cGMP manufacturing. The purification process
resulted in greater than 98% pure rBoNTE(Hc) based on HPLC and yielded up to 1.01 g of rBoNTE(Hc)/kg cells
at the bench scale and 580 mg vaccine/kg cells at the pilot scale. N-terminal sequencing showed that the purified
rBoNTE(Hc) N-terminus is intact and was found to protect mice against a challenge of 1000 mouse
intraperitoneal LD50’s of BoNT/E.
Keywords: Botulinum; Pichia pastoris; Ion-exchange chromatography; Hydrophobic charge induction
chromatography; Homogenized; Filtration; Recombinant protein; Scale-up

Comments: This paper was originally published in the Journal of “Protein Expression and Purification” 45
(2006) 359–367 © 2005 Elsevier Inc.

Botulinum neurotoxin, a National Institute of Allergen and Infectious Disease class A agent, has been
weaponized [1]. There is a need for a safe, well characterized, and efficacious recombinant vaccine that will
protect against all seven known serotypes of the toxin. Such a product is needed to protect US military
personnel, first-responders in the civilian environment, and, if necessary, civilians who may be at risk because
of their geographical locations in the United States. Clostridium botulinum produces seven antigenically distinct
neurotoxins differentiated serologically by specific neutralization [2]. These have been designated as serotypes
A through G and are the most toxic substances known [3]. Thus, seven monovalent vaccines are required if full
immunologic protection against botulinum neurotoxins is to be achieved. The botulinum toxin is expressed as a
single, 150-kDa polypeptide chain that is post translationally nicked, forming a simple two-chain polypeptide
that consists of a C-terminal 100kDa heavy chain joined by a single disulfide bond to the 50-kDa light chain [4].
The toxin has three distinct regions: a translocation domain, a binding domain, and a catalytic domain. The
carboxy terminus of the heavy chain binds to a nerve cell receptor at the neuromuscular junction [5] and the
amino terminus of the heavy chain is capable of forming channels in the cell membrane, allowing internalization
2+
of the toxin [6,7]. Finally, the toxin’s light chain, a Zn -containing endoprotease, is released into the cell
cytoplasm, cleaving a specific synaptic protein involved in the docking of acetylcholine-containing vesicles
from binding to the synaptic membrane. This blocking prevents the vesicles from releasing acetylcholine into
the synapse at the neuromuscular junction, resulting in flaccid muscle paralysis [8]. In humans, botulism is
characterized by a descending flaccid paralysis, starting in the head region and descends to the muscles
controlling breathing.

The Hc fragments of BoNT (A–F) were shown to be non-toxic, antigenic [9], and capable of eliciting a
protective immunity in animals challenged with homologous BoNT [10, 11]. These results prompted an effort to
develop a recombinant botulinum vaccine against all seven serotypes using the Hc fragments as vaccine antigens
[4,12–17]. As mentioned earlier, the seven serotypes are distinct antigenitically, requiring the vaccine to be
comprised of seven distinct antigens. To add to the complexity, the heavy chain fragments for each of the seven
serotypes are distinct proteins with variable degrees of homology. By way of illustration, the isoelectric points
of the recombinant fragments calculated from the known sequences are as follows: serotype A: 9.3, B: 7.1, C:
5.6, D: 6.0, E: 8.3, F: 9.1, G: 7.9, underscoring the fact that fermentation and puriWcation of each antigen will
be unique. It was the hope back in 1994 when the University of Nebraska-Lincoln Biological Process
Development Facility (BPDF) began working with Dr. Leonard Smith of the United States Army Medical
Research Institute of Infectious Diseases (USAMRIID) on this project that once a fermentation and purification
process was developed for BoNTB(Hc) [13] that all subsequent serotypes would follow suite. This was found
not to be the case for BoNTA(Hc) [14] and continues to be the case for each of the serotypes we have worked
on. The experiences we learned from previous purification research are applied to the next serotype, but the
amount expressed during fermentation, the methods of purification, and the characteristics of the molecules are
different for each serotype. There in lies the challenge of a recombinant botulinum vaccine, seven different
processes to produce seven different proteins, with all seven distinct Hc fragments formulated into one vial.
This paper describes research, development, and scale up of a process to produce a recombinant botulinum
1
neurotoxin serotype E, heavy chain C-terminal fragment (rBoNTE(Hc)) candidate vaccine suitable for transfer
to a current good manufacturing practice (cGMP) facility for production of clinical material. The rBoNTE(Hc)
fragment is expressed intracellularly in Pichia pastoris using a three-phase high-cell density fermentation
incorporating a 9 h methanol induction to minimize proteolytic degradation of the rBoNTE(Hc). Initial process
development was performed at the bench scale resulting in a four-step process and concluded with four benchscale demonstration runs to determine process reproducibility. Two pilot-scale runs were performed to

demonstrate the scalability of this process for continuation towards the goal of cGMP manufacturing.
Materials and methods
Molecular biology
rBoNTE(Hc) gene was originally obtained from C. botulinum NCTC 11219. At the Division of Toxicology
and Aerobiology of USAMRIID, rBoNTE(Hc) codon optimized gene was inserted into pHILD4 expression
vector at EcoRI site. After transformation into P. pastoris GS115 (his4), cells were screened with increasing
amount of Genticin (G418) to determine a multi-copy expression vector. The multi-copy clone developed at
USMRIID was then tested for viability and restriction map of the insert by Southern blot.
Fermentation
Pichia pastoris GS115 harboring three copies of the rBoNTE(Hc) encoding gene with expression under the
control of AOX1 promoter was grown to high cell density on defined medium. The fermentation was carried out
in three different phases, i.e., glycerol batch phase, glycerol fed-batch phase, and the methanol fed-batch phase.
Fermentations were performed in 5 L fermentor (BioXo 3000, New Brunswick Scientific Edison, NJ) or in 19 L
fermentor (NLF, Bioengineering AG, Sagenrainstrasse 7 CH-8636 Wald, Switzerland) at pH 5.0 and 30 °C. The
cells were grown to desired cell density on glycerol and then induced on methanol for expression as previously
described
1

Abbreviations used: BCA, bicinchoninic acid; rBoNT, recombinant botulinum neurotoxin; rBoNTE(Hc),
recombinant botulinum neurotoxin serotype E, heavy chain C-terminal fragment; BSA, bovine serum albumin;
CV, column volume; FF, fast Xow; HP, high performance; Hc, heavy chain C-terminal fragment; kDa, kilo
Dalton; MW, molecular weight; PVDF, polyvinylidene diXuoride; Q, quaternary amine; SDS–PAGE, sodium
dodecyl sulfate–polyacrylamide gel electrophoresis; SP, sulfopropyl; HCIC, hydrophobic charge induction
chromatography; WCW, wet cell weight; TBS, Tris base-buVered saline; PMSF, phenylmethylsulfonyl
Xuoride; IEC, ion-exchange chromatography; cGMP, current good manufacturing practices; SEC, size
exclusion chromatography; SCX, strong cation exchange chromatography; HIC, hydrophobic induction
chromatography; PDS, puriWed drug substance; NaCl, sodium chloride; i.p., intraperitoneal.
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[13,14,17]. The cells were grown exponentially on methanol containing 12 mL/L of PTM1 salts [18] and
induced for 9 h. Samples were withdrawn for analyses to determine the wet cell weight and rBoNTE(Hc)
production.
Bench-scale cell harvest and disruption
Cells were harvested by centrifugation at 11,300g at 4°C for 30 min using a Sorvall Evolution RC Centrifuge
(Kendro Laboratory Products, Asheville, NC). Cell paste was either frozen at 80 °C or processed immediately.
¡

Two hundred grams of cell paste was suspended in 50 mM sodium phosphate mono basic, 10 mM sodium
chloride (NaCl), and pH 7.4, to 20% (w/v) solids to wash the fermentation medium away. The suspension was
centrifuged at 11,300g at 4 °C for 15 min. Cell paste was resuspended in 50 mM sodium phosphate mono basic,
10 mM NaCl, pH 7.4 to 20% (w/v) solids and homogenized using a Microfluidizer M-110EH (Micro fluidics,
Newton, CA) set at 22,000 psi with the lysate chilled to <10 °C before processing. Two passes were performed
to obtain at least 85% cell disruption determined with a hemocytometer. The homogenate was clarified at
11,300g for 30 min at 4 °C followed by filtration through a Pall AcroPak 200 with a 0.2 m Fluorodyne II
membrane (Pall, East Hills, NY) and loaded immediately onto the first column.

Bench-scale purification
All bench-scale chromatographic separations were performed on a BioCad Workstation (Applied Biosystems,
Foster City, CA) at room temperature, with the load material placed on ice. A 5.0 cm 19.5 cm column (Waters
£

Chromatography, Milford, MA) packed with 383 mL of strong cation exchange SP Sepharose Fast Flow resin
(Amersham Biosciences Piscataway, NJ) was equilibrated with 5 column volumes (CV) of 50 mM sodium
phosphate mono basic, 10 mM NaCl, pH 7.4. Supernatant was loaded onto the column at a linear velocity of
300 cm/h followed by a 10 CV wash with the equilibration buffer. The product was eluted using a 5 CV step of
50 mM sodium phosphate mono basic and 100 mM NaCl, pH 7.4.
The SP Sepharose FF product was loaded directly onto a 2.7 cm 19.8 cm column (Applied Biosystems,
£

Foster City, CA) packed with 113 mL strong anion exchange Q Sepharose Fast Flow resin (Amersham
Biosciences Piscataway, NJ). The column was equilibrated with 5 CV of 50 mM sodium phosphate mono basic,
pH 7.4 at a linear velocity of 300 cm/h. The flow through fraction was collected from the Q Sepharose FF
column as the rBoNTE(Hc) does not bind and passes through the column.
The Q Sepharose FF product was diluted with an equal volume of 25 mM succinate, pH 4.0 to bring down the
pH to approximately pH 6.0. The diluted product was loaded onto a 2.7 cm 13.1 cm (Applied Biosystems,
£

Foster City, CA) 75 mL strong cation exchange SP Sepharose HP resin (Amersham Biosciences Piscataway,
NJ) that was pre-

equilibrated with 5 CV of 25 mM succinate, pH 6.0 at 200 cm/h. After loading, the column was washed with 5
CV of 25 mM succinate, 200 mM NaCl, pH 5.0 buffer. The rBoNTE(Hc) was eluted from the column using a 25
CV linear gradient from 25 mM succinate, 200 mM NaCl, pH 5.0 to 25 mM succinate, 300 mM NaCl, pH 5.0.
The SP Sepharose HP product was diluted with an equal volume of 50 mM sodium phosphate mono basic,
pH 7.4 to adjust the pH up to 6.0. The diluted product was loaded onto a 2.7 cm 13.6 cm (Applied Biosystems,
£

Foster City, CA) 77 mL hydrophobic charge induction chromatography column, BioSepra MEP HyperCel resin
(Ciphergen, Fremont, CA) and equilibrated with 5 CV of 25 mM succinate, pH 6.0 at 300 cm/h. After loading,
the column was washed with 5 CV of 25 mM succinate, pH 5.0 buVer. rBoNTE(Hc) was eluted from the
column using a 15 CV linear gradient from 25 mM succinate, pH 5.0 to 25 mM succinate, pH 4.0.
The final product was dia-filtered with 15 mM succinate pH 4.0 using Millipore Pellicon XL Filter, with a 50
2
cm 10K regenerated cellulose membrane (Millipore, Bedford, MA) until the final product reached a pH of 4.0.

The purified drug substance was sterile filtered with an AcroPak 20, with a 0.2 μm Fluorodyne II membrane
(Pall, East Hills, NY) and stored at 2–8 °C (Table 1).
Pilot-scale cell harvest and disruption
Cells harvested from 19L fermentation were centrifuged at 11,300g at 4 °C for 30 min using a Sorvall
Evolution RC Centrifuge (Kendro Laboratory Products, Asheville, NC) and processed immediately. Thousand
three hundred to thousand five hundred grams of cell paste were suspended in 50 mM sodium phosphate mono
basic, 10 mM NaCl, pH 7.4 to 20% (w/v) solids to remove fermentation medium. The suspension was
centrifuged at 11,300g for 15 min and resuspended in 50 mM sodium phosphate mono basic, 10 mM NaCl, pH
7.4 to 20% (w/v) solids. Cells were homogenized using a Microfluidizer M-110EH (Microfluidics, Newton,
CA) set at 22,000 psi. Two passes were performed to obtain at least 85% cell disruption determined with a
hemocytometer. The homogenate was centrifuged at 11,300g for 30min at 4°C and filtered through a Pall 0.2
μm Fluorodyne II membrane (Pall, East Hills, NY) prior to loading onto the first column.
Pilot-scale purification
All chromatographic separations were performed using a North Carolina SRT (Cary, NC) pilot-scale
chromatography skid. All chromatographic conditions were the same as the bench-scale work, i.e., linear
velocities, equilibration, washing, and elution methods. The SP Sepharose FF step was performed using a 3.14L
(20cm 10cm) BPG 200/500 column (Amersham Pharmacia Biotech, Piscataway, NJ). The Q Sepharose FF
£

step was performed on a 1.02L (10cm 13cm) BPG 100/500 column (Amersham Biosciences Piscataway, NJ).
£

The SP Sepharose HP step was performed using a 557mL (7cm

£

10 cm) QS 70/500 column (Millipore,

Bedford, MA), and the BioSepra MEP HyperCel step was performed using a 531mL (6cm 18.8 cm) Vantage
£

60A column (Millipore, Bedford, MA). Final product was dia-filtered to pH 4.0 using 15mM succinate, pH 4.0
2
at 5 °C with a North Carolina SRT Optisep 3000 bench filtration unit equipped with two 2ft of 10kDa
regenerated cellulose, part number 52-D5B-0010 (North Carolina SRT Cary, NC). Final product was sterile
filtered with an AcroPak 20, with a 0.2 μm Fluorodyne II membrane (Pall, East Hills, NY) and stored at 2–8 °C

Protein analysis
Total protein concentrations were determined using the BCA (Pierce Chemical, St. Louis, MO) standard
assay, using BSA as a standard. Purity was determined by SDS– PAGE using 10% Bis–Tris gels with Mops
buffer system (Novex, San Diego, CA) stained with Coomassie blue. Western blot analysis was performed
using polyclonal chicken anti-rBoNTE(Hc) antibody incubated at 0.33 μg/ mL for 1 h at room temperature. The
secondary antibody was a peroxidase labeled affinity-purified goat anti-chicken IgG (Kirkegaard & Perry
Laboratories, Gainsburg, MD) incubated at 0.15 μg/mL for 1 h at room temperature. The SDS–PAGE-separated
proteins were transferred to PVDF membranes (Bio-Rad, Hercules, CA) at 25 V for 20 min, blocked with 5%
non-fat dried milk for 30 min and washed with Tris base-buffered saline (TBS) prior to treatment with
antibodies. Blots were then visualized by chemiluminescence using the ELC plus Detection Kit (Amersham
Pharmacia Biotech, Piscataway, NJ). Protease detection was performed with an Enz-Chek Protease Assay Kit
(Molecular Probes, Eugene, OR) with Bodipy FL Casein as the substrate. N-terminal sequencing was performed
by the University of Nebraska-Medical Center Protein Core Facility using a ABI Procise 494 Sequencer
(Applied Biosystems, Foster City, CA) (Table 3). The Biological Process Development Facility (BPDF) Quality
Control Laboratory estimated purity and quantity of rBoNTE(Hc) by HPLC using strong cation exchange
chromatography (SCX). SCX analysis was performed with a 50 mm length PolyLC Polysulfoethyl A column
(PolyLC, Columbia, USA). For sample analysis a 1 mL/min gradient elution from 65% mobile phase A (20 mM
Tris at a pH 7.7) and 35% mobile phase B (20 mM Tris, 2 M NaCl at a pH 7.7) to 60% mobile phase A and 40%
mobile phase B, over 6 min.
Mouse potency bioassay
The potency of purified rBoNTE(Hc) was determined using a mouse potency bioassay [19,20]. Groups of 10

female mice (stain Crl:CD-1 (Charles River, NC)) were intramuscularly vaccinated twice with threefold
dilutions of antigen (8.1, 2.7, 0.9, 0.3, 0.1, 0.033, and 0.011 μg rBoNTE(Hc)/mouse). The antigen was
formulated in 25 mM succinate, 15 mM phosphate, pH 5.0, and diluted into final concentrations of 0.2%
Alhydrogel (HCI Biosector, Frederikssund, Denmark), 5% mannitol, 0.9% NaCl, pH 5.5. Vaccinations were at
2-week intervals, and the mice were challenged 3 weeks after the final vaccination with 1000 mouse i.p., LD50
BoNT/E toxin complex. Mice were observed twice daily for 5 days post challenge. Results were tabulated and
analyzed using probit analysis (SPSS, Chicago, IL).
Results and discussion
Fermentation
It was determined that after 9 h of methanol induction the amount of rBoNTE(Hc)/unit cell did not increase
and that intracellular protease levels increased by nearly 50% as the induction time increased to 26 h. P. pastoris
GS115 rBoNTE(Hc) induced on methanol for 26 h produced increased level of proteases that were detrimental
to the stability of rBoNTE(Hc) during the purification process and under final product storage conditions. The 9
h induction time was chosen.
Bench-scale purification
Initial cell disruption experiments consisted of four passes through the Microfluidizer as described in Material
and methods section. It was found by bicinchoninic acid (BCA), Western blot assays, and the hemocytometer,
that after two passes the protein concentration and the intensity of Western blot bands on subsequent passes
were the same. Two passes were also advantageous since this reduced the total processing time of the
homogenization step, reducing the potential for proteolytic degradation of rBoNTE(Hc). If homogenate was
stored at 2–8 °C for 24 h, the rBoNTE(Hc) would degrade to multiple fragments based on Western blot. The
length of the methanol induction had an impact on the quality of the product as mentioned above. Initially, 2
mM phenylmethylsulfonyl fluoride (PMSF) was added to the cell suspension just prior to disruption to inhibit
protease activity and prevent the formation of degradation products. From a cGMP perspective, PMSF is not
desirable, and should be removed prior to scale-up. Adding 10 mM NaCl to the breaking buffer reduced the
binding of proteases to the SP Sepharose Fast Flow resin during the capture step and optimizing
chromatography conditions resulted in additional protease activity eluting during the wash step (Fig. 1). A
combination of 9 h methanol induction time, a short processing time for harvested cells, and optimization of the
separation of proteases from the rBoNTE(Hc) during the capture step eliminated the need for PMSF in the
homogenization buffer.
The rBoNTE(Hc) was purified at the bench scale using ion-exchange and hydrophobic charge induction
chromatography techniques. Batch binding studies evaluated both anion and cation exchange resins over a pH
range from 4 to 8 for capture of rBoNTE(Hc). Clarified cell lysate at a protein/resin ratio of 5 mg/mL was
incubated at 4 °C for 3 h. Optimum binding was based on the least amount of rBoNTE(Hc) present in the
supernatant. Batch and dynamic binding were compared at a total protein load of 20mg/mL of resin followed by
a step elution using 300 mM NaCl. Surprisingly, 78.2 mg/g total protein of rBoNTE(Hc) was recovered from
dynamic binding to the capture column, while only 33.9 mg rBoNTE(Hc)/g of total protein was recovered from
batch binding. This was over a twofold increase in the amount of rBoNTE(Hc) recovered from the first step.
Initial elution of the rBoNTE(Hc) from the SP Sepharose FF column was achieved using a 300 mM NaCl step
elution in 50 mM sodium phosphate buffer at pH 7.4. Further optimization determined that rBoNTE(Hc) eluted
off at 100 mM NaCl. This decreased the amount of contaminants and eliminated a major contaminant at the
same MW as the rBoNTE(Hc) (Fig. 2). The maximum total protein loaded onto the SP Sepharose FF column
was 55 mg/ mL resin.

Product from the capture column was negatively puri-fied through a Q Sepharose FF column removing a
majority of the larger molecular weight Pichia proteins that are present after the capture step (Fig. 3). Analysis
of the eluted contaminants by Western blot found that rBoNTE(Hc) was not present at a protein load of 5.5
mg/mL resin at the bench scale. This protein load was used for future processing runs and scale-up.
The flow through from the Q Sepharose FF column was loaded directly onto a SP Sepharose HP resin.
Initially a Source 15 S resin was used for this step, but due to scalability problems and the cost of this resin, a
resin screen was performed using Poros 50 HS, SP Sepharose HP, CM 650 M, Source 30 S, and Fractrogel
EMD. Based on the results of the resin screen and factoring in cost, SP Sepharose HP resin was selected. The
SP Sepharose HP resin increased the purity of rBoNTE(Hc) to 92% based on strong cation exchange (SCX)HPLC. The elution gradient was optimized from a 45 CV gradient of 100–400 mM NaCl in 25 mM succinate,
pH 5.0 to a 25 CV gradient of 200– 300 mM NaCl in 25 mM succinate, pH 5.0.
Hydrophobic charge induction chromatography (HCIC) was used as a polishing step to remove degradation

Fig. 1. Protease detection during the capture of rBoNTE(Hc). A chromatogram of the capture step for a benchscale purification of rBoNTE(Hc) with no PMSF in the cell lysate shown with the corresponding specific
activity’s of proteases in each of the fractions taken during the separation with bodipy casein used as the
substrate.

Fig. 2. Capture step optimization. Coomassie-stained SDS–PAGE and Western blot of fractions taken across the
elution peaks of the SP Sepharose FF capture step, used for determining the optimal NaCl step elution.
product of rBoNTE(Hc) (Fig. 4 and Table 4). A total pro-the degraded rBoNTE(Hc) from the intact
rBoNTE(Hc), tein load of 3.5 mg/mL resin resulted in no rBoNTE(Hc) the degraded rBoNTE(Hc) comes from
the omission of detected in the flow through. By collecting only the back half of the elution peak (Fig.4) it was
possible to separate the degraded rBoNTE(Hc) from the intact rBoNTE(Hc), the degraded rBoNTE(Hc) comes
from the omission of PMSF in the lysis buffer. The purified drug substance half of the elution peak (Fig. 4) it
was possible to separate (PDS) was shown to be a single band on SDS–PAGE

Fig. 3. SDS–PAGE of chromatography products. SDS–PAGE of the different product peaks from all the
chromatography steps in the rBoNTE(Hc) purification process with an equal total protein load across the gel.
Lane 1, See Blue Plus 2MW Marker; lane 2, cell lysate; lane 3, Sp Sepharose FF product; lane 4, Q Sepharose
FF product; lane 5, SP Sepharose HP product; and lane 6, HCIC product.

(Figs. 3 and 4) and >98% by SCX-HPLC (Table 4). The pH of the PDS as it eluted from the HCIC column is
approximately pH 4.7. By SDS–PAGE, it has been demonstrated that the PDS will degrade over a 4 day period
at 4 °C if the pH of the PDS is above a pH 4.7. However, the protein has been shown to be stable over the same
storage period at 4 °C following reduction of the pH to pH 4.0 prior to storage (Figs. 5 and 6). The entire
purification process from harvesting to final sterile-filtering at the bench scale was performed with in 10 h.
Four bench-scale purification runs were performed to determine the robustness of the process. The PDS from
these runs were very similar in purity and elution profiles.

Fig. 4. HCIC chromatogram and SDS–PAGE. Chromatogram and SDS–PAGE of the HCIC column step
showing how the degradation product is remove across the elution of the rBoNTE(Hc) peak. Lane 1, See Blue
plus 2 MW Marker; lane 2, HCIC load; lane 3, HCIC fraction 1; lane 4, HCIC fraction 2; lane 5, HCIC fraction
3; lane 6, HCIC fraction 4; and lane 7, HCIC fraction 5.

Fig. 5. Stability of rBoNTE(Hc) at pH 5.0. The stability of rBoNTE(Hc) in a pH 5.0 buffer stored at 4 °C for 4
days shown by SDS–PAGE. Lane 1, See Blue plus 2 MW Marker; lane 2, rBoNTE(Hc)-DP-007 Day 0; lane 3,
rBoNTE(Hc)-DP-007 Day 1; lane 4, rBoNTE(Hc)-DP-007 Day 2; lane 5, rBoNTE(Hc)-DP-007 Day 3; and lane
6, rBoNTE(Hc)-DP-007 Day 4.

Fig. 6. Stability of rBoNTE(Hc) at pH 4.0. The stability of rBoNTE(Hc) in a pH 4.0 buffer stored at 4 °C for 4
days shown by SDS–PAGE. Lane 1, See Blue plus 2 MW Marker; lane 2, rBoNTE(Hc)-DP-007 Day 0; lane 3,
rBoNTE(Hc)-DP-007 Day 1; lane 4, rBoNTE(Hc)-DP-007 Day 2; lane 5, rBoNTE(Hc)-DP-007 Day 3; lane 6,
and rBoNTE(Hc)-DP-007 Day 4.
The yields ranged from 577 mg of purified rBoNTE(Hc)/ kg cell mass to 1 g of purified rBoNTE(Hc)/kg cell
mass (Table 1), and yield varied based on the cut on the final HCIC column. Analysis by N-terminal sequencing
showed the rBoNTE(Hc) to have an intact N-terminus (Table 2).
Pilot-scale purification
Two 19 L fermentations and two pilot-scale purifications runs were performed. These fermentations resulted
in final wet cell weights of 175 and 139 g/L with final volumes of 10.2 and 11.8 L, respectively.
The first pilot-scale purification was performed using freshly harvested cell mass and produced 462 mg
PDS/kg cell mass. Upon completion of the run, analysis showed the final product to contain a minor, lower
molecular weight form of rBoNTE(Hc) by SDS–PAGE and was 97% pure by SCX-HPLC. This contaminant
was due to fraction selection during the HCIC column step. N-terminal sequencing determined the PDS had an
intact N-terminus (Table 2).
A second pilot-scale purification generated a 100% pure product based on SCX-HPLC and no lower
molecular weight form of rBoNTE(Hc) was seen by SDS–PAGE. The second pilot-scale run also produced a
higher over all yield (Table 3). The product was collected from the HCIC chromatography step just before the
apex of the peak, consistent with the bench-scale runs. The HPLC analysis indicated (data not shown) that the
lower molecular weight contaminant elutes from the column at the beginning of the peak and the pure
rBoNTE(Hc) elutes at the end of the peak. A residual DNA test was performed on the final product (AppTec,
Philadelphia, PA) and was below the limit of detection (<5 pg DNA/100 g of rBoNTE(Hc)). N-terminal
sequencing determined the PDS had an intact N-terminus (Table 2).
Mouse potency assay
A mouse bioassay was used to determine rBoNTE(Hc) vaccine potency. Material from the second production
runs was used for vaccinations. Potency assay results (Fig. 7) showed protection to be centered, with an ED50
(effective dose protecting half the mice) of 190 ng, having 95% confidence limits of 38–678 ng. The potency of
this rBoNTE(Hc)

Fig. 7. Potency plot. Plot of the number of surviving mice vs. the microgram dosage of rBoNTE(Hc).
preparation is roughly equivalent to potencies of other rBoNT vaccines, which range from 89 to 116 ng [19].
Conclusion
The production and purification of recombinant heavy chain fragment C of botulinum neurotoxin serotype E
from P. pastoris GS115 using the process described above has been scaled-up and resulted in similar product
purity at both the bench and pilot scales. The rBoNTE(Hc) was most stable stored at a pH of 4.0 in 15 mM
succinate. During the HCIC purification step, in the future it is recommended that SCX-HPLC should be used as
an in-process assay to adequately determine the proper fraction selection, to avoid including the lower
molecular contaminant in the PDS. During these studies our objective was to use peak shape to determine
fraction selection. Though this works, to optimize yield, in-process analysis is recommended. The purification
process required four chromatographic steps with no ultra filtration steps between each chromatography step.
The formulation step required a membrane dia filtration. The product was intact and comparable in potency to
other rBoNT vaccines.
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